Clinical Trials Logo

Clinical Trial Summary

The objective of this research is to characterize the urinary metabolites produced after the consumption of mango pulp in an effort to begin to characterize the bioavailability of the major group of polyphenolics in mango, ester-linked gallic acids, and to provide new insight into their in vivo physiological behavior.


Clinical Trial Description

Eleven healthy volunteers (2 male, 9 female) who had no medical history of digestive disorders or chronic diseases participated in the 10-day mango consumption study. They were aged between 21-38 years and with a weight between 45-95 kg. Participants were asked to stop taking dietary supplements for 1 week prior to the study begin and study duration and asked to avoid excessive exercise and alcohol consumption 3 days prior to the start of the study day 1 and study day 10. Participants were also required to fill out a 72-hour nutritional report at home that detailed their food consumption over the previous 3 days leading up to the first and tenth day and were reviewed for compliance. All participants fasted from fruit and vegetables, coffee and tea one day prior to study day 1 and 10 and were asked to bring in a stool sample collected prior to consumption of mango on the first day of the study. After an overnight fast of at least 12 hours, urine collections were made (baseline) and a baseline blood draw was taken from each participant. Each participant was given 400 grams of mango to consume and urine collections were made at 0-3, 3-6, 6-8, and 8-12 hours. The volume of urine was recorded and an aliquot immediately frozen at -80°C until analysis. Blood samples were also taken at 0.5, 1, 2, 3, 4, 6, 8, and 12hrs, collected in heparinized tubes and centrifuged for 10 mins at 4000 x g, 4°C. Supernatant (plasma) was aliquoted into 2mL samples, acidified with 50 μL 85% formic acid, and immediately frozen at -80° C until analysis. Participants were given 400 grams of mango to consume daily for the next eight days and the study design was repeated again on the 10th day. After completion of the tenth day of study, stool samples were collected and immediately frozen at -20°C for microbial analysis. ;


Study Design

Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science


Related Conditions & MeSH terms


NCT number NCT02227615
Study type Interventional
Source Texas A&M University
Contact
Status Active, not recruiting
Phase N/A
Start date March 2013
Completion date December 2017

See also
  Status Clinical Trial Phase
Completed NCT04078646 - Influence of Proteins on the Bioavailability of Carotenoids N/A
Completed NCT04355286 - Bemotrizinol UV Filter Part 1 Clinical PK Evaluation in Topical MUsT Study Phase 1
Completed NCT05328271 - A Pilot Study to Determine the Bioavailability of Oral Beta-Aminoisobutyric Acid (BAIBA) Ingestion N/A
Completed NCT03807050 - Safety and Pharmacokinetics of Phaffia Rhodozyma Astaxanthin N/A
Completed NCT05277376 - Pharmacokinetic (PK) Evaluation of Bemotrizinol (6%) in a Sunscreen Maximum Usage Trial Phase 3
Completed NCT05032807 - Pharmacokinetic Study of a Novel Lipid Formulation of Cannabidiol Compared to a Standard Formulation Phase 1
Completed NCT05076890 - Hemp 15 mg & 50 mg Capsule Absorption N/A
Completed NCT03433040 - 17OHP-C Dosing Among Obese Pregnant Women Phase 3